People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who ...

MG-ADL (Myasthenia Gravis - Activities of Daily Living) provides a rapid clinical assessment of the patient's recall of symptoms impacting activities of daily living, with a total score range of 0 to ...

J&J exhibited additional findings, displaying that nipocalimab met its key secondary endpoint, a change in QMG score.

Generalised myasthenia gravis (gMG) is a chronic disorder in which the body's immune system mistakenly targets the neuromuscular junctions—areas where nerves signal muscles to move. This ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

About S-1117 S‑1117 is a novel engineered Fc-fused pan-IgG protease targeting IgG autoantibodies engineered with Seismic’s IMPACT platform ... which may result in superior clinical outcomes in ...